Stockreport

European Commission Approves Astellas' PADCEV™ (enfortumab vedotin) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Urothelial Cancer [Yahoo! Finance]

ASTELLAS PHARMA UNSP/ADR  (ALPMY) 
NASDAQ:AMEX Investor Relations: astellas.com/jp/en/investors
PDF - European Marketing Authorization based on positive overall survival and progression-free survival results from the global Phase 3 EV-302 trial TOKYO Aug. 28, 2024 / [Read more]